Overview

AXIS 2: AX200 for the Treatment of Ischemic Stroke

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of AX200 (filgrastim) in the treatment of acute ischemic stroke and to assess the safety and tolerability of AX200.
Phase:
Phase 2
Details
Lead Sponsor:
Sygnis Bioscience GmbH & Co KG
Treatments:
Lenograstim